Advanced Track (SBER)
2019 AER Conference
C19 - Risk Mitigation in Mixed SBER and Biomedical Research
.jpg "Lara N. Sloboda, PhD <br> photo")
Lara N. Sloboda, PhD
Associate Director of Research, Dana Farber Cancer Insititute
Matt D. Stafford, MPH
Assistant Director, Clinical Research Compliance, Boston Children's Hospital
Co-Chair, Regulatory Working Group and SBER Subcommittee, Harvard Catalyst
Speaker(s)
Using case studies, this session will focus on risk mitigation in research involving both biomedical and social science methods. Case studies will include piloting initiatives to overcome reluctance to utilize support/recovery services for persons affected by opioid abuse, and an evaluation of an early intervention program to ameliorate psychosocial effects of Chronic Traumatic Encephalopathy in youth who play contact sports. Before attending this session, attendees should have a basic foundation in human research protections ethics and principles, including the criteria for approval and definitions from HHS and FDA regulations. During this session, speakers and attendees will:
Learning Objectives:
- Review the nature of the risks, harms, and impacts associated with mixed SBER/biomedical research
- Explore factors likely to contribute to increased risk in research spanning both medical and social/behavioral arenas
- Discuss how to design research with sufficient protections and minimize risk through study design